⚠ STRICT REGULATORY DIRECTIVE: B2B BIOLOGICAL API SUPPLY ONLY

Shaanxi Sunrise Pharmaceutical Co., Ltd. operates strictly as an industrial biological raw material supplier. The Pembrolizumab API (CAS: 1374853-91-4) discussed below is intended exclusively for biopharmaceutical R&D, in-vitro assay development, companion diagnostic (CDx) manufacturing, and biosimilar scale-up. It is NOT a finished clinical drug product and is strictly prohibited for direct human or veterinary therapeutic administration.

As we navigate the biological manufacturing landscape of 2026, the global discussion surrounding Pembrolizumab has evolved. The initial clinical shockwaves have settled. Today, pharmaceutical procurement directors and R&D laboratories face a mature, highly technical stage of development. The operational focus has violently shifted toward high-concentration subcutaneous stability, the explosion of the biosimilar market, and the uncompromising logistical challenges of maintaining intact tertiary protein structures across a global supply chain.

At Shaanxi Sunrise, we supply more than just biochemical raw materials. We deliver the analytical predictability and technical clarity required to execute 2026's most aggressive oncology innovations. We eliminate lot-to-lot variance. We eradicate immunogenic aggregates. We secure your pipeline.

While Pembrolizumab remains the undisputed pillar of PD-1 inhibition, 2026 is officially the era of Combination Therapy. The massive B2B demand we process today is driven directly by advanced laboratories testing the synergistic lethality between this monoclonal antibody and newer agents, such as CTLA-4 inhibitors or anti-angiogenic Tyrosine Kinase Inhibitors (TKIs).

This "1+1 > 2" strategy raises the biochemical bar higher than ever before. It is no longer just about procuring the correct CAS 1374853-91-4 sequence. When you mix biological macromolecules with harsh small-molecule environments or novel buffer systems, the risk of protein unfolding and aggregation skyrockets. If your API contains undetected micro-aggregates, it will trigger artificial immunogenicity in your sensitive in-vivo models, completely invalidating your pre-clinical data.

We solve this at the purification level. Shaanxi Sunrise utilizes advanced Size-Exclusion High-Performance Liquid Chromatography (SEC-HPLC) to guarantee a monomer purity of ≥ 99.0%. We mathematically eliminate the high-molecular-weight species that cause combination therapies to fail in the vial.

Pembrolizumab's unique "tissue-agnostic" regulatory designation remains its most powerful academic and commercial weapon. Treating malignant tumors based strictly on their Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) genetic footprint—rather than their anatomical location—has rewritten the rules of oncology.

This genetic-first model has inspired a massive wave of B2B interest from pharmaceutical sponsors developing secondary formulations for highly refractory tumors where traditional surgical resection or radiation protocols fail. To run these complex, multi-cohort pan-tumor xenograft models, research institutions require massive, uninterrupted volumes of stable API. Shaanxi Sunrise provides scalable, commercial-grade batch sizes that allow your R&D department to execute massive tissue-agnostic screening programs without ever encountering lot-to-lot conformational variance.

The global pharmaceutical industry is rapidly and violently pivoting from lengthy Intravenous (IV) infusions to rapid Subcutaneous (SC) injections. Make no mistake: this is not merely a packaging change. It is a fundamental protein engineering challenge.

"To achieve the necessary therapeutic dose within a 1 mL to 2 mL subcutaneous injection volume, formulators must pack the antibody to concentrations frequently exceeding 100 mg/mL. At these extreme densities, non-covalent protein-protein interactions cause liquid viscosity to spike exponentially, rendering the formulation unsyringeable."

If your starting biological raw material is compromised, it will precipitate immediately upon concentration. At Shaanxi Sunrise, our API structural integrity must be flawless. We are actively supplying ultra-high-purity biological grades to formulators currently developing cutting-edge hyaluronidase-based (rHuPH20) SC delivery systems. Our optimized charge variant profiles (monitored via cIEF) ensure that your high-concentration formulations remain fluid, stable, and highly bioavailable.

Audit our 2026 biological release specifications. We exceed basic industry standards to protect your downstream applications:

1. How does the 2026 "Biosimilar Wave" affect procurement strategy?
With key patents nearing expiration, the global market is currently flooded with generic alternatives. However, analytical consistency is the ultimate risk. Shaanxi Sunrise focuses strictly on providing high-purity intermediates that allow biosimilar developers to maintain exact proteomics matching and identical glycosylation mapping. We ensure your biosimilar candidates survive the most rigorous regulatory comparability audits.

2. What are the storage and logistical requirements for bulk international shipments?
Monoclonal antibodies are highly fragile macromolecules susceptible to thermal denaturation. We utilize advanced 2026-grade cold-chain logistics systems, maintaining strictly validated environments at -20°C or deep-freeze at -80°C as required by your formulation. Every single international shipment includes embedded, tamper-proof data-loggers to prove zero temperature excursions occurred. We guarantee the protein's tertiary structure has not been compromised during global transit.

3. Is your material suitable for Companion Diagnostic (CDx) development?
Yes. In the era of precision oncology, treating without testing is obsolete. Many of our premier biopharma clients utilize our high-purity Pembrolizumab powder as an absolute control standard for developing highly sensitive PD-L1/TPS diagnostic assay kits. Our lack of background impurities makes it the ideal baseline for diagnostic calibration.

Stop risking your multi-million dollar pre-clinical models on biological raw materials that fail baseline stability testing. Secure the exact analytical specifications required for your formulation scale-up.

Request Technical Data & Global B2B Pricing:
Contact the Shaanxi Sunrise engineering team for batch-specific Certificates of Analysis (COAs), comprehensive MSDS documentation, and custom volume quotes.

• Supplier: Shaanxi Sunrise Pharmaceutical Co., Ltd.

• Official Site: www.pharma-sunrise.com

• Direct Procurement Email: betty@pharma-sunrise.com

• Market Analysis: Global Monoclonal Antibody Procurement Trends & Biosimilar Impact 2026.

• Journal of Clinical Oncology: Long-term Efficacy and Pharmacokinetics of MSI-H Agnostic Therapies.

• Internal Audit Data: Shaanxi Sunrise Internal Quality Control Protocols (ISO 9001:2015).